Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) early breast cancer (EBC) patients face long-term recurrence risk despite standard treatment. Here, NR4A1 is linked to breast cancer.